"New directions in science are launched by new tools much more often than by new concepts. The effect of a concept-driven revolution is to explain old things in new ways.
various disciplines and specialties. Now, this field will have a multidisciplinary community of its own that by design spans multiple industries (Table 1) .
Digital Biomarkers will be electronic, open access, and for at least the first year article processing charges will be waived. We will also bring the content to you through a periodic news update delivered to you electronically. In addition to providing you with the top research findings in the field, we will with time bring you interviews with the leading thinkers, curated content, and other information to keep you abreast of developments of the field.
Like traditional journals, Digital Biomarkers will have rigorous peer review to ensure that the best articles are brought to you. To assist us with this effort, we have assembled an outstanding Editorial Board with expertise in computer science, bioinformatics, regulatory science, drug development, and medicine from around the world. We value their time and that of authors. As such, we will be rigorous in our selection of papers that are sent for peer review so that reviewers do not have their time wasted on papers that are not likely suitable for this journal and so that authors can quickly find a more suitable journal.
Given the multidisciplinary nature and intended broad audience of the journal, we will want articles to be clear [4, 5] and to minimize jargon, including abbreviations. If a concept is complicated, make it simple. Teach the reader, give examples, draw analogies, and be visual. Unlike many journals, we want value, and would love to feature creative visuals (figures, tables, drawings, and videos) that help explain and demonstrate the findings of your work. In addition, as a digital journal, we seek to serve as a repository for data, algorithms, and applications that can be a resource for all. We also want your help and suggestions for how to make Digital Biomarkers valuable. If you know someone (including yourself) who would be excellent addition to our Advisory or Editorial Board, tell us (dib@karger.com). If you have a suggestion for an important topic or author, let us know. If you think we should use the journal to house data, catalog digital biomarkers, follow clinical trials using them, track regulatory approvals of digital biomarkers, cover a conference, interview leaders in the field, contact us and, even better, help lead that effort. We welcome new ideas and will support the ones consistent with our mission.
The launching of Digital Biomarkers is the culmination of contributions from many including our outstanding Advisory Board of luminaries in the field who have provided guidance on the structure and priorities of the journal, foster the development of relationships within the community, and suggested our distinguished Editorial Board members. The Editorial Board serves as the resource for intellectual content for the journal and community, 
